Full Press Release Details
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure.
LXRX
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
Key Takeaway: New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
Price reaction · baseline $1.98 (2024-07-12 close) · 1 other LXRX headline(s) in the window, move may be shared
day 0 close
+7.1%
day 1 · peak
+12.6%
day 3
+5.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus